228 related articles for article (PubMed ID: 22091682)
1. Novel therapies in melanoma.
Scheier B; Amaria R; Lewis K; Gonzalez R
Immunotherapy; 2011 Dec; 3(12):1461-9. PubMed ID: 22091682
[TBL] [Abstract][Full Text] [Related]
2. [BRAF mutation: a novel approach in targeted melanoma therapy].
Arenbergerová M; Puzanov I
Klin Onkol; 2012; 25(5):323-8. PubMed ID: 23102192
[TBL] [Abstract][Full Text] [Related]
3. Melanoma brain metastasis: overview of current management and emerging targeted therapies.
Fonkem E; Uhlmann EJ; Floyd SR; Mahadevan A; Kasper E; Eton O; Wong ET
Expert Rev Neurother; 2012 Oct; 12(10):1207-15. PubMed ID: 23082737
[TBL] [Abstract][Full Text] [Related]
4. The conquest of melanoma by immunotherapy.
Lejeune FJ
Melanoma Res; 2015 Oct; 25(5):373-5. PubMed ID: 26173006
[No Abstract] [Full Text] [Related]
5. Advances in the management of melanoma: targeted therapy, immunotherapy and future directions.
Dean E; Lorigan P
Expert Rev Anticancer Ther; 2012 Nov; 12(11):1437-48. PubMed ID: 23249108
[TBL] [Abstract][Full Text] [Related]
6. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
Ravnan MC; Matalka MS
Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
[TBL] [Abstract][Full Text] [Related]
7. Upcoming strategies for the treatment of metastatic melanoma.
Spagnolo F; Queirolo P
Arch Dermatol Res; 2012 Apr; 304(3):177-84. PubMed ID: 22350184
[TBL] [Abstract][Full Text] [Related]
8. [Melanoma- finally good news].
Wicki A; Arnold AW; Itin PH; Zippelius A
Praxis (Bern 1994); 2013 May; 102(11):667-70. PubMed ID: 23692905
[TBL] [Abstract][Full Text] [Related]
9. Developing melanoma therapeutics: overview and update.
Korman JB; Fisher DE
Wiley Interdiscip Rev Syst Biol Med; 2013; 5(3):257-71. PubMed ID: 23408545
[TBL] [Abstract][Full Text] [Related]
10. Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient.
Peters S; Bouchaab H; Zimmerman S; Bucher M; Gaide O; Letovanec I; Homicsko K; Michielin O
Melanoma Res; 2014 Oct; 24(5):496-500. PubMed ID: 25185693
[TBL] [Abstract][Full Text] [Related]
11. Melanoma: diagnosis, staging, and treatment. Consensus group recommendations.
Berrocal A; Cabañas L; Espinosa E; Fernández-de-Misa R; Martín-Algarra S; Martínez-Cedres JC; Ríos-Buceta L; Rodríguez-Peralto JL
Adv Ther; 2014 Sep; 31(9):945-60. PubMed ID: 25145549
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
Owen JL; Lopez IE; Desai SR
J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
[TBL] [Abstract][Full Text] [Related]
13. FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation.
Kim G; McKee AE; Ning YM; Hazarika M; Theoret M; Johnson JR; Xu QC; Tang S; Sridhara R; Jiang X; He K; Roscoe D; McGuinn WD; Helms WS; Russell AM; Miksinski SP; Zirkelbach JF; Earp J; Liu Q; Ibrahim A; Justice R; Pazdur R
Clin Cancer Res; 2014 Oct; 20(19):4994-5000. PubMed ID: 25096067
[TBL] [Abstract][Full Text] [Related]
14. Unexpected recalcitrant course of drug-induced erythema multiforme-like eruption and interstitial pneumonia sequentially occurring after nivolumab therapy.
Nomura H; Takahashi H; Suzuki S; Kurihara Y; Chubachi S; Kawada I; Yasuda H; Betsuyaku T; Amagai M; Funakoshi T
J Dermatol; 2017 Jul; 44(7):818-821. PubMed ID: 28295542
[TBL] [Abstract][Full Text] [Related]
15. Vemurafenib: a guide to its use in unresectable or metastatic melanoma.
Keating GM; Lyseng-Williamson KA
Am J Clin Dermatol; 2013 Feb; 14(1):65-9. PubMed ID: 23329082
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy in managing metastatic melanoma: which treatment when?
Amaral T; Meraz-Torres F; Garbe C
Expert Opin Biol Ther; 2017 Dec; 17(12):1523-1538. PubMed ID: 28891339
[TBL] [Abstract][Full Text] [Related]
17. Which drug, and when, for patients with BRAF-mutant melanoma?
Jang S; Atkins MB
Lancet Oncol; 2013 Feb; 14(2):e60-9. PubMed ID: 23369684
[TBL] [Abstract][Full Text] [Related]
18. Vemurafenib for the treatment of melanoma.
Jordan EJ; Kelly CM
Expert Opin Pharmacother; 2012 Dec; 13(17):2533-43. PubMed ID: 23094782
[TBL] [Abstract][Full Text] [Related]
19. Impact of MET expression on outcome in BRAF(V600E/K) advanced melanoma.
Jubb AM; Ribas A; Sosman JA; McArthur GA; Yan Y; Rost S; Zhao S; Koeppen H
Histopathology; 2013 Sep; 63(3):351-61. PubMed ID: 23802768
[TBL] [Abstract][Full Text] [Related]
20. The European Medicines Agency review of vemurafenib (Zelboraf®) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use.
da Rocha Dias S; Salmonson T; van Zwieten-Boot B; Jonsson B; Marchetti S; Schellens JH; Giuliani R; Pignatti F
Eur J Cancer; 2013 May; 49(7):1654-61. PubMed ID: 23481513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]